Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Novartis Partner on Cancer Diagnostic

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmacogenomic test development firm Foundation Medicine today announced a collaboration with Novartis to develop, enhance, and optimize Foundation's cancer genome panel test.

The deal is Foundation's first with a drug firm, and if the pilot phase is successful the two companies will evaluate opportunities to commercialize the test.

"By delivering a clinical-grade analysis of molecular information, Foundation's dedicated clinical research team will help our partners more rapidly translate novel findings into therapeutically applicable results," Alexis Borisy, CEO of Cambridge, Mass.-based Foundation, said in a statement. "This collaboration is an important step forward for Foundation and could provide us with the basis for building successful cancer genome analysis platforms for future collaborations and partners."

Financial and other terms of the deal were not disclosed.

Privately-held Foundation raised $25 million in a Series A round of financing last April.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.